Cellcolabs completes first stem cell trial for knee osteoarthritis

Abu Dhabi has achieved a significant milestone in medical innovation by successfully completing its first stem cell trial for knee osteoarthritis (OA). Conducted between November 2023 and October 2024, the trial involved 50 patients who received a single ultrasound-guided injection of 50 million mesenchymal stem cells (MSCs) derived from healthy donors aged 18 to 30. The procedure was performed at Burjeel Medical City and Burjeel Hospital under the leadership of Dr. Oussama Chaar and Dr. Veerabahu Muthusamy.

The MSCs, developed by Swedish biotech company Cellcolabs and branded as StromaForte, function as biological mediators. Instead of replacing damaged tissue, they stimulate the body's natural repair mechanisms, reduce inflammation, and promote tissue regeneration.

The trial's primary endpoint was safety, which was confirmed by an independent safety monitoring board. Patients reported significant reductions in pain levels, improved mobility, and enhanced quality of life, with no serious adverse events.

This achievement underscores Abu Dhabi's growing prominence as a hub for medical research and innovation. The Department of Health – Abu Dhabi (DoH) emphasized that the trial reflects the emirate's robust regulatory oversight and commitment to advancing regenerative medicine.

MRI scans were conducted to further evaluate the therapy's efficacy, with detailed findings expected to be presented at Abu Dhabi Global Health Week in April 2025.

This pioneering trial offers new hope for knee OA patients, providing a potential non-surgical alternative to alleviate pain and improve joint function.

Sources:

(https://www.onearabia.me/, Gulf Today)
(totaluae.com)
(Gulf Today,
The Finance 360)
(https://www.onearabia.me/,
The Finance 360)
(https://www.onearabia.me/)
(Al Jundi)